Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion with Voyager Therapeutics.
The news is a positive note amongst a fair amount of doom-and-gloom in the hopes of finding a treatment for Alzheimer’s in the near future, perhaps exemplified best by Pfizer’s decision to exit the neuroscience area at the beginning of the year.
